Application of 12-Ketolithocholic Acid in the Preparation of Anti-Streptococcus pharyngitis Products
By preparing 12-ketolithocholic acid antibacterial agents and additives, the drug resistance problem of Streptococcus pharyngitis was solved, achieving effective inhibition and treatment of Streptococcus pharyngitis infection, and providing a new treatment method.
Patent Information
- Application Number
- CN202311376447.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-23
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-10-23
AI Technical Summary
There are no reports on the application of 12-ketolithocholic acid in the preparation of anti-streptococcal products in the prior art, and infections caused by streptococcal pharyngitis have a high risk of drug resistance and severe systemic infection, and there is a lack of effective treatment methods.
Using 12-ketolithocholic acid or its pharmaceutically acceptable salt, antibacterial agents, drugs, or additives are prepared for the production of products that inhibit Streptococcus pharyngitis infection and growth, including dosage forms such as emulsions, ointments, aerosols, suspensions, wettable powders, powders, and aqueous solutions, with concentrations ranging from 3 to 400 μg/mL.
12-Ketolithocholic acid exhibits good inhibitory activity against the growth of Streptococcus pharyngitis, with an IC50 of 3.805 μg/mL. It is effective in treating Streptococcus pharyngitis infection and related diseases, and has broad application prospects.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004508180940000011
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biopharmaceutical technology, specifically relating to the application of 12-ketolithocholic acid in the preparation of anti-pharyngeal streptococcal products. Background Technology
[0002] Streptococcus anginosus (S. anginosus), an opportunistic pathogen, is a common cause of infections. Its clinical manifestations vary, and treatment methods and prognoses differ significantly. It frequently causes abscesses in various organs and tissues, as well as purulent infections in other sites. Previous studies have confirmed that Streptococcus anginosus can produce various exotoxins that cause invasive purulent infections. Once it invades the bloodstream, it can circulate throughout the body, causing severe infectious diseases involving systemic infection, poisoning, and systemic inflammatory responses. The condition is often quite dangerous, and the prognosis is poor if timely anti-infective treatment is not initiated. Bacterial resistance is a global problem. The development of new drugs is of significant reference value in reducing antibiotic use and preventing the emergence of drug-resistant bacteria.
[0003] Bile acids are an active component of bile and an important part of bile digestion. Changes in their levels are of significant reference value in the diagnosis of liver diseases, and they also have anti-tumor effects. 12-Ketolithocholic acid is one of the most important secondary bile acids in the intestine, but there are currently no reports of its application in the preparation of anti-streptococcal products for pharyngitis. Summary of the Invention
[0004] The purpose of this invention is to provide the application of 12-ketolithocholic acid in the treatment of streptococcus pharyngitis.
[0005] The technical solution adopted in this invention is: A first aspect of the invention provides the use of 12-ketolithocholic acid or a pharmaceutically acceptable salt thereof in the preparation of products for treating streptococcal pharyngitis infection.
[0006] A second aspect of the invention provides the use of 12-ketolithocholic acid or a pharmaceutically acceptable salt thereof in the preparation of products that inhibit the growth of Streptococcus pharyngitis.
[0007] A third aspect of the invention provides the use of 12-ketolithocholic acid or a pharmaceutically acceptable salt thereof in the inhibition of the growth of Streptococcus pharyngitis for non-disease diagnostic and therapeutic purposes.
[0008] A fourth aspect of the invention provides the use of 12-ketolithocholic acid or a pharmaceutically acceptable salt thereof in the preparation of products for the prevention and / or treatment of diseases caused by Streptococcus pharyngitis.
[0009] Preferably, the diseases caused by Streptococcus pharyngitis include otitis media, sinusitis, intracranial abscess, gingivitis, periodontitis, dental abscess, pneumonia, lung abscess, pleural empyema, and intra-abdominal infection.
[0010] Preferably, the product includes antibacterial agents, drugs, or additives.
[0011] Preferably, the additives include feed additives or hygiene product additives.
[0012] Preferably, the product also includes pharmaceutically acceptable excipients and additives.
[0013] Preferably, the excipients include at least one of the following: carrier, diluent, excipient, lubricant, adhesive, wetting agent, disintegrant, solvent, emulsifier, cosolvent, solubilizer, preservative, pH adjuster, osmotic pressure adjuster, surfactant, coating material, antioxidant, or buffer.
[0014] Preferably, the dosage form of the product is selected from at least one of emulsions, ointments, aerosols, suspensions, wettable powders, powders, granules, and aqueous solutions.
[0015] A fifth aspect of the invention provides a product comprising 12-ketolithocholic acid or a pharmaceutically acceptable salt thereof; The product has at least one of the following functions: A1. Anti-streptococcal infection of the pharynx; A2. Inhibits the growth of Streptococcus pharyngitis; A3. Prevention and / or treatment of diseases caused by Streptococcus pharyngitis.
[0016] Preferably, the product includes antibacterial agents, drugs, or additives.
[0017] Preferably, the additives include feed additives or hygiene product additives.
[0018] A sixth aspect of the present invention provides a method for inhibiting the growth of Streptococcus pharyngitis for non-disease diagnosis and treatment purposes, comprising the following steps: The growth of Streptococcus pharyngitis is inhibited by using 12-ketolithocholic acid or a pharmaceutically acceptable salt thereof, or by the product described in the fifth aspect of the invention.
[0019] Preferably, the working concentration of the 12-ketolithocholic acid is 3 to 400 μg / mL.
[0020] Preferably, the working concentration of the 12-ketolithocholic acid is 3 to 100 μg / mL.
[0021] The beneficial effects of this invention are: This invention is the first to discover that 12-ketolithocholic acid can inhibit the growth of Streptococcus pharyngitis, with an IC50 of 3.805 μg / ml. Therefore, 12-ketolithocholic acid can be used to prepare products that are effective against Streptococcus pharyngitis, thereby effectively treating Streptococcus pharyngitis infection or diseases caused by Streptococcus pharyngitis infection; it has great application prospects. Attached Figure Description
[0022] Figure 1 : Relationship between 12-ketolithocholic acid concentration and growth inhibition rate of Streptococcus pharyngitis.
[0023] Figure 2 Graph showing the relationship between chloramphenicol concentration and the growth inhibition rate of Streptococcus pyogenes. Detailed Implementation
[0024] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.
[0025] In this embodiment, Streptococcus pharyngitis ATCC9895 was purchased from Ningbo Mingzhou Biotechnology Co., Ltd. 12-ketolithocholic acid and chloramphenicol were both commercially available products. The specific information of 12-ketolithocholic acid is as follows: Product No.: 700239P; Brand: Avanti. The specific information of chloramphenicol is as follows: Product No.: 56757; Brand: MACKLIN.
[0026] Example 1 1. Sample preparation 1.1 Test sample: 12-ketolithocholic acid; molecular weight: 390.56 g / mol; Before use, the test sample should be prepared with ethanol to a maximum concentration of 50 mg / mL, and then diluted sequentially by 1 / 2.
[0027] 1.2 Reference standard: Chloramphenicol.
[0028] 2. Test strains and culture methods The test strain was Streptococcus pharyngitis ATCC9895, and the culture conditions were: Brain-Heart Infusion (BHI), incubated at 37°C for 24-48 hours.
[0029] The specific cultivation steps are as follows: 2.1 Initiation and culture of bacterial strains Wipe the ampoule clean with cotton wool soaked in 75% alcohol. Heat the tip of the ampoule with a flame, and drip a small amount (2-3 drops) of sterile water onto the heated tip to break it. Use a file or tweezers to tap off the broken tip of the ampoule, and then flame the opening of the lyophilized tube. Use a sterile pipette to draw 0.3 ml of sterile water and drip it into the lyophilized tube, gently shaking until dissolved. Collect the entire bacterial suspension and inoculate it onto Columbia blood agar. Incubate at 37°C for 24 hours. After that, pick a single colony and culture it in liquid medium under the same conditions for enrichment.
[0030] 2.2 Preparation of bacterial working solution When the OD600 value reaches around 0.6 (approximately 10... 9 The bacterial suspension (CFU / ml) was serially diluted in BHI broth (0, 10, 100, 1000, 10000, 100000, 100000, 10000 times). 100 μL of the suspension was inoculated onto a solid culture medium and cultured for 24 h. The viable cell count was then performed, and the bacterial suspension concentration was calculated. This suspension was then further diluted to a final concentration of approximately 2 × 10⁻⁶ CFU / ml. 6 CFU / ml. All bacterial strain operations were performed under aseptic conditions. After the experiment, all consumables were sterilized and then discarded.
[0031] 3. Determination of the minimum inhibitory concentration (MIC50) required to inhibit 50% of the test bacteria. 3.1 Test method: The MIC50 was determined by the micro-broth dilution method.
[0032] The experiment was divided into a positive control group (bacterial suspension without the drug), a negative control group (culture medium containing ethanol as the solvent), and experimental groups (bacterial suspensions containing different concentrations of 12-ketolithocholic acid). Each group had three replicates. The 300 μg / mL 12-ketolithocholic acid experimental solution was serially diluted in liquid culture medium to final concentrations of 300 μg / mL, 150 μg / mL, 75 μg / mL, 37.5 μg / mL, 18.75 μg / mL, 9.375 μg / mL, 4.6875 μg / mL, and 0 μg / mL. The concentration was 2 × 10⁻⁶. 6 CFU·mL -1 100 μL of bacterial suspension and each group of drug solutions were mixed at a 1:1 ratio and inoculated into sterile 96-well plates to achieve a final bacterial suspension concentration of 1 × 10⁻⁶. 6 CFU / mL (containing 10) 5 CFU / well) were placed under appropriate culture conditions and incubated for 24 h.
[0033] Simultaneously, chloramphenicol was prepared as a control, with final concentrations of 32 μg / mL, 16 μg / mL, 8 μg / mL, 4 μg / mL, 2 μg / mL, 1 μg / mL, and 0 μg / mL. After incubation, the lowest drug concentration at which no bacterial growth was observed in the petri dish against a black background was defined as the minimum inhibitory concentration (MIC) of 12-ketolithocholic acid. The IC50 assay was repeated three times for all bacterial strains.
[0034] The OD600 value of suspended bacterial cells was measured. The method for calculating the inhibition rate of test samples and control samples at different concentrations was as follows: Inhibition rate (%) = 1 - (OD value of test sample / control sample - OD value of negative control) / (OD value of positive control - OD value of negative control) × 100%. The MIC50 was calculated by curve fitting to obtain a function.
[0035] The results of this experiment are shown in Tables 1 and 2, and the inhibition rate graph is shown in Table 2. Figures 1-2 The experiment is only meaningful when bacteria grow significantly in the positive control well (i.e., without the drug).
[0036] Table 1: Absorbance values of different concentrations of 12-ketolithocholic acid on the growth of Streptococcus pharyngitis
[0037] Table 2: Absorbance measurements of the effect of different concentrations of chloramphenicol on the growth of Streptococcus pyogenes
[0038] The results showed that bacteria grew normally in the positive control wells (i.e., without the drug), while no sterile growth was observed in the solvent control wells. The MIC value of chloramphenicol against Streptococcus pyogenes was 4 μg / mL, which meets the standard of ≤4 μg / mL for chloramphenicol against Streptococcus pyogenes in the National Committee for Clinical Library Standardization (NCCLS) 2001, "Standards for the Implementation of Antimicrobial Susceptibility Testing: 11th Edition Information Supplement M100-S11," indicating that this experimental method is reliable.
[0039] Statistical results showed that the IC50 of 12-ketolithocholic acid against the tested Streptococcus pharyngitis was 3.805 μg / mL. These results indicate that 12-ketolithocholic acid has good inhibitory activity against Streptococcus pharyngitis, and the findings are intended to provide a reference for clinicians in the prevention and control of Streptococcus pharyngitis.
[0040] The above detailed embodiments have provided a comprehensive description of the present invention. However, the present invention is not limited to the above embodiments. Within the scope of knowledge possessed by those skilled in the art, various changes can be made without departing from the spirit of the present invention. Furthermore, unless otherwise specified, the embodiments of the present invention and the features thereof can be combined with each other.
Claims
1.12-Ketolithocholic acid or a pharmaceutically acceptable salt thereof in the preparation of a product for treating streptococcal infection of the pharynx, said product being a drug or an antibacterial agent. 2.12-Ketolithocholic acid or a pharmaceutically acceptable salt thereof in the preparation of a product for inhibiting the growth of Streptococcus pharyngitis, said product being a drug or an antibacterial agent. 3.12-Ketolithocholic acid or a pharmaceutically acceptable salt thereof in the preparation of products for the prevention and / or treatment of diseases caused by Streptococcus pharyngitis, said products being pharmaceuticals or antibacterial agents.
Citation Information
Patent Citations
Application of deoxycholic acid in preparation of product for resisting streptococcus mitis
CN115531394A
Application of 12-ketolithocholic acid in preparation of anti-Vihonor product
CN119632998A
